Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

< b > Conditions < /b > :   Meningitis;   Meningococcal Meningitis;   Meningococcal Infections < br/ > < b > Interventions < /b > :   Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine;   Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine;   Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine;   Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine < br/ > < b > Sponsor < /b > :   Sanofi Pasteur, a Sanofi Company < br/ > < b > Recruiting < /b > - verified July 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials